The treatment success rate for extensively drug-resistant tuberculosis in Brazil is forecasted to remain relatively stagnant from 2024 to 2028, showing only a slight increase from 20% in 2024 and 2025 to 21% from 2026 onwards. In 2023, the treatment success rate stood at 20%, indicating minimal year-on-year improvement with only a 1% rise expected from 2025 to 2026. The Compound Annual Growth Rate (CAGR) over this five-year period remains negligible, reflecting ongoing challenges in enhancing treatment outcomes.
Future trends to watch for include developments in medical technology, new drug approvals, and health policy changes that could potentially accelerate improvements in treatment success rates. Enhanced healthcare infrastructure and increased funding for research and patient care could also contribute towards more significant gains in future outcomes.
